Tumor Biology Journal Citation Rate 2026
1010-4283
eISSN 1423-0380
SAGE Publishing
CH
Q1 Quartile Open Access Established Impact
About Tumor Biology
Tumor Biology (TB) is a peer-reviewed academic journal covering Cancer Cells and Metastasis and Cancer-related molecular mechanisms research, published by SAGE Publishing in CH, catalogued under ISSN 1010-4283 (e-ISSN 1423-0380). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 3.18 (Q1 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It is fully open access, with an Article Processing Charge (APC) of approximately $2000 USD.
Tumor Biology Citation Rate 2026 — In Context
Tumor Biology has a 2025 2-Year Citation Rate (OpenAlex) of 3.18, placing it in the Q1 quartile within the Cancer Cells and Metastasis research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
As a fully open-access publication, Tumor Biology makes all articles freely available to readers for an Article Processing Charge of approximately $2000 USD.
Researchers looking to publish in Tumor Biology should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Tumor Biology against similar journals in the field, use our journal comparison tool.
Submission Tips for Tumor Biology
- Budget $2000 for the Article Processing Charge. Check if your institution or funder covers OA fees.
- This journal covers Cancer Cells and Metastasis, Cancer-related molecular mechanisms research, Circular RNAs in diseases. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Tumor Biology Compares
Compared against 23 journals in the same research areas.
| ISSN (Print) | 1010-4283 |
|---|---|
| ISSN (Online) | 1423-0380 |
| Publisher | SAGE Publishing |
| Country | Switzerland |
| APC / Cost | $2000 USD |
In-depth profile & metrics
Tumor Biology is published by SAGE Publishing and based in Switzerland. It publishes open access with an article-processing charge of USD 2000.
In our subject taxonomy, Tumor Biology is classified under Cancer Cells and Metastasis, Cancer-related molecular mechanisms research, Circular RNAs in diseases and MicroRNA in disease regulation.
Tumor Biology is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.
Its most recent citation rate stands at 3.176.
Research Areas
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Tumor Biology
Live Indexing Status
Updated April 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2025 | 3.176 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Compare Journals
Compare Tumor Biology against similar publications in its field:
Related Journals in Your Field
-
Journal of Experimental & Clinical Cancer Research BioMed Central IF 10.31
-
Theranostics Ivyspring International Publisher IF 10.23
-
Cancer Biology & Therapy Taylor & Francis IF 6.11
-
Breast Cancer Research BioMed Central IF 4.57
-
Structure Elsevier BV IF 3.96
Explore More Journals
Metadata
Last updated: Apr 24, 2026
Updated by: openalex_bulk
OpenAlex ID: S12644804
Get weekly updates for Cancer Cells and Metastasis journals
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.